Drug Profile
Bone marrow mesenchymal stem cell therapy - Beike Biotech
Alternative Names: BM-MSCLatest Information Update: 16 Oct 2021
Price :
$50
*
At a glance
- Originator Beike Biotechnology
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Spinal cord injuries
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Spinal-cord-injuries in China (IM, Injection)
- 31 Oct 2006 Preclinical trials in Spinal cord injuries in China (IM)